 |
 |
 |
 |
 |
 |
 |
|
Board of Directors |
|
R. Ian Lennox
Director
Mr. Lennox
is Chairman of Ricerca Biosciences LLC and an
experienced board member and business executive in the
life sciences industry. He has served
as President & CEO, MDS Pharmaceutical & Biotechnology
Markets, President & CEO, MDS Drug Discovery &
Development Sector, President & CEO, Phoenix
International Life Sciences, CEO, Drug Royalty
Corporation and as the President & CEO of Monsanto
Canada. He currently serves as a director of MSBi
Ventures, MERGE Healthcare and the Company. His previous
board experience includes serving as Chairman of
Stressgen Biotechnologies Corporation, Labopharm Inc.
and Drug Royalty Corp. and as a Director of GenSci
Regeneration Inc., Marsulex Inc., Hemosol Inc. and MDS
Capital (Venture) Corp. Mr. Lennox received an Honours
B. Sc. degree in physiology and pharmacology and an
M.B.A. from The University of Western Ontario and has
completed the executive management program in finance at
the Columbia School of Business.
|
| |
|
Paul Walker,
M.D., Ph.D., F.R.C.S.C
Director
President & Chief Executive Officer
Spectral Diagnostics, Inc.
Dr. Walker left the position of COO of the Toronto
General Hospital to join Spectral Diagnostics Inc. as
President and CEO in April 2001. Previously, Dr. Walker was
Surgeon in Chief and Vice President of the Surgical
Directorate of the University Hospital Network. Dr. Walker
was an active Vascular Surgeon and the Director of the
Intensive Care Program, and Professor of Medicine and
Laboratory Medicine at the University of Toronto. Dr.
Walker received his M.D from the University of Western
Ontario, his Ph.D from the Salgrenska University of Göteborg
Sweden, and is the author of over 100 scientific
publications. Dr. Walker is a graduate of the Advanced
Management Program from Harvard School of Business. |
| |
Anthony
Bihl
Director
Mr. Bihl is an experienced
executive with more than 25 years in leadership of
global healthcare businesses, including a broad base
of operational and executive positions in large and
medium multinational healthcare firms. Mr.
Bihl is the Chief Executive Officer of American
Medical Systems and he has over 25 years experience
in financial, operational, and global management and
medical instrument manufacturing. From 2000 to 2007,
Mr. Bihl served various senior leadership positions
at Siemens AG, formerly Bayer Healthcare, including
Vice President of Finance and Control, Senior Vice
President of Business Planning and Administration,
President of Diagnostics Division, and most
recently, as CEO of Siemens Medical Solutions
Diagnostics.
|
|
|
Kevin A Giese, B.A., Llb, M.B.A.
Director
Mr. Giese has a B.A. in economics, a
law degree, and an M.B.A. He has practiced law in
Vancouver, was president of Mr. Lube U.S. (acquired by
Pennzoil), was a director and CFO of TSX-listed NQL
Drilling Tools (acquired by National Oilwell Varco), and
has sat in management roles and on the board of
directors of a number of private and other TSX listed
companies. He is a past advisory board member of the
Institute of Corporate Directors (Canada) and is
currently a member of the Board of Directors of
BioAlberta. Kevin Giese is the founding President, CEO
and Director of
Medwell Capital Corp. (formerly BioMS Medical Corp.),
a biotechnology company
dedicated to the development and commercialization of
innovative therapies, with an emphasis on the treatment
of Multiple Sclerosis. In 2005 he received the
BioAlberta Award for Entrepreneurship.
|
| |
|
Mr. Guillermo Herrera
Director
Mr. Herrera
is a seasoned global healthcare executive with more than
25 years of experience. Mr. Herrera spent 24 years at
Abbott Laboratories, most recently serving as Senior
Vice President, International Operations and President
of Abbott International. In this role, Mr. Herrera was
accountable for International Commercial Operations
including sales and marketing of pharmaceutical,
nutritional and hospital products in markets outside the
US. In 2004, Mr. Herrera joined Rosetta Partners LLC
as the Partner and Principal in charge of the private
equity division. Mr. Herrera received a BA in
Industrial Economics from the Universidad del Valle,
Colombia, and his MBA from the Kellogg Graduate School
of Management at Northwestern University.
|
| |
|
|
Edward E.
McCormack
Director
Mr. McCormack is an independent business consultant. From
1987 to 1999 he was the Senior Vice-President, Chief
Financial Officer and a Director of Novopharm Limited, one
of North America’s largest generic pharmaceutical product
manufacturers. Mr. McCormack was also the President of Almad
Investments Limited and Beaver Power Corporation, investment
companies associated with Novopharm Limited. Mr. McCormack’s
financial background includes specific experience in private
placements, bank financing and restructuring, acquisitions
and divestitures. He is a member of the Ontario Institute of
Chartered Accountants and the former Chairman of the Board
and Chairman of the Audit Committee at Hemosol Corp. |
| |
|
Laine Woollard, Q.C.
Director
Mr.
Woollard has degrees in Pharmacy and Pharmaceutical
Science, passing the Pharmaceutical Examining Board
of Canada examinations in 1983, and in Law, having
become a Member of the Alberta Bar in 1987. Mr.
Woollard has been corporate counsel and practiced in
the field of technology commercialization since
1990, joining the University of Alberta in 1994. He
has served on the Board of Directors of six
for-profit corporations. Mr. Woollard has been lead
independent director of
Medwell Capital Corp. (formerly BioMS Medical Corp.)
since
2005 and is also chairman of the corporate
governance committee, member of the compensation
committee and past chairman of the audit and
compensation committee. Laine Woollard, QC is
Senior Legal Counsel of TEC Edmonton which was
formed in mid-2004 as a joint venture between the
University of Alberta and Edmonton Economic
Development Corporation (EEDC).
|
|
|
|
 |
|